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Abstract
Background: Collaborative care is an effective treatment for the management of depression but evidence on its cost-
effectiveness in the UK is lacking.
Aims: To assess the cost-effectiveness of collaborative care in a UK primary care setting.
Methods: An economic evaluation alongside a multi-centre cluster randomised controlled trial comparing collaborative care
with usual primary care for adults with depression (n = 581). Costs, quality-adjusted life-years (QALYs), and incremental cost-
effectiveness ratios (ICER) were calculated over a 12-month follow-up, from the perspective of the UK National Health
Service and Personal Social Services (i.e. Third Party Payer). Sensitivity analyses are reported, and uncertainty is presented
using the cost-effectiveness acceptability curve (CEAC) and the cost-effectiveness plane.
Results: The collaborative care intervention had a mean cost of £272.50 per participant. Health and social care service use,
excluding collaborative care, indicated a similar profile of resource use between collaborative care and usual care
participants. Collaborative care offered a mean incremental gain of 0.02 (95% CI: –0.02, 0.06) quality-adjusted life-years over
12 months, at a mean incremental cost of £270.72 (95% CI: –202.98, 886.04), and resulted in an estimated mean cost per
QALY of £14,248. Where costs associated with informal care are considered in sensitivity analyses collaborative care is
expected to be less costly and more effective, thereby dominating treatment as usual.
Conclusion: Collaborative care offers health gains at a relatively low cost, and is cost-effective compared with usual care
against a decision-maker willingness to pay threshold of £20,000 per QALY gained. Results here support the commissioning
of collaborative care in a UK primary care setting.
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Introduction
Depression is a long term and disabling condition with well
documented negative impacts on health status and on health care
resources [1,2]. In most cases the responsibility for treatment of
people with depression falls on primary care [3], but the
organisation of care in this setting can face many challenges.
These include barriers between generalist and specialist mental
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health professionals, poor patient adherence to pharmacological
treatment [4], and a shortage of specialists to provide psycholog-
ical therapies [5]. Against this backdrop there is a growing role for
organisational interventions to support the management of
depression, and collaborative care has been shown to be an
effective intervention that supports the organisation of health care
for depression [6]. Collaborative care is a complex intervention,
developed in the United States, incorporating a multi-professional
approach to patient care; a structured management plan;
scheduled patient follow-ups; and enhanced inter-professional
communication [7]. In practice this is achieved by the introduction
of a care manager into primary care, responsible for delivering
care to patients with depression under supervision from a
specialist, and for liaising between primary care clinicians and
mental health specialists. Systematic reviews, of studies mostly
conducted in the United States, demonstrate that collaborative
care improves depression outcomes [6,8], and a recent randomised
control trial, the CADET Trial of collaborative care for depression
in UK primary care, has shown it to be effective in the UK
healthcare system [9]. Evidence indicates that collaborative care is
cost-effective in the setting of the United States healthcare system
[10,11], however, evidence on the cost effectiveness of collabora-
tive care for depression in the UK has been lacking until now
[10,11]. We report here the results of an economic evaluation of
collaborative care versus usual care carried out in the UK
alongside the CADET trial.
Methods
Study/Trial design
The aim of the CADET trial (Trial Registration Number:
ISRCTN32829227) was to determine the effectiveness and cost-
effectiveness of collaborative care when added to usual care
compared to usual care alone in the management of patients with
moderate to severe depression in UK primary care. The design of
this multi-centre, two group cluster randomised controlled trial,
and methods for the economic evaluation, are described in detail
in the published protocol [12]. In brief, we recruited participants
from electronic case records of general practices in three UK sites:
Bristol, London and Greater Manchester. Recruitment included
patients newly identified as depressed, with or without one or more
previous depressive episodes, and those with an existing diagnosis
of depression which was not responding to primary care
management. Eligible participants were people aged 18+ who
met ICD-10 criteria for a depressive episode on the revised
Clinical Interview Schedule (CIS-R) [13]. Ethical approval for the
trial on which this economic evaluation is based was given by the
UK NHS Health Research Authority, NRES Committee South
West (NRES/07/H1208/60). All participants gave written
informed consent before taking part in the study. No minors/
children were enrolled in the study. Written consent forms were
co-signed by participant and the person taking consent, and were
securely stored in both original form and electronically. The ethics
approval included approval of both the procedure and the forms
and documentation used for consent. We excluded those at high
risk of suicide, psychosis, bi-polar disorder, those whose depression
was associated with bereavement, people whose primary present-
ing problem was alcohol or drug abuse, and those receiving
psychological treatment for their depression via mental health
services. We randomly allocated practices into collaborative care
or usual care, using a minimisation approach, to minimise
imbalance between treatment groups, using site (Bristol, London.
Manchester), Index of Multiple Deprivation (IMD) rank [14],
number of GPs, and practice size.
Interventions
Participants allocated to the control condition, treatment as
usual (TAU), received care from their general practitioner
according to usual clinical practice for these patients, including
treatment by antidepressants and referral for other treatments,
including UK Improving Access to Psychological Therapies
(IAPT) services.
The collaborative care intervention consisted of usual care from
the GP, and additionally care managers were expected to provide
between 6–12 contacts with participants over a period of 14 weeks:
with these expected to comprise 30–40 minutes for one initial face
to face appointment followed by 15–20 minute telephone contacts
thereafter. Contacts included: education about depression; med-
ication management; behavioural activation [15]; and relapse
prevention instructions [16]. Care managers provided GPs with
advice on medication and regular updates on patient progress
including medication adherence.
Care managers had existing UK mental health qualifications
(psychological wellbeing practitioners, counsellors or nurses) and
were then trained specifically to deliver the intervention within the
collaborative care framework. They received weekly supervision
from a specialist mental health professional, a clinical psychologist,
psychiatrist, an academic GP with special interest in mental health
or a senior nurse psychotherapist. Individual patients were
discussed in supervision at least monthly, facilitated through a
bespoke computerised patient management system (PC-MIS-
http://www.pc-mis.co.uk).
Outcome measures
Clinical effectiveness was assessed using depression severity as
the primary outcome, measured by the Patient Health Question-
naire-9 (PHQ-9) [17]. The PHQ-9 is a nine-item questionnaire,
which records the core symptoms of depression, with scores
ranging from 0 to 27 where higher scores indicate a greater
severity of depression. Secondary outcomes were quality of life
using the SF-36 [18], worry and anxiety using the GAD-7 [19],
patient satisfaction using the CSQ8 [20], health care service use
using a patient questionnaire, and health state values (health-
related quality-of-life) using the EQ-5D 3L [21,22]. All measures
were collected at baseline, four months and 12 months post
randomisation (except patient satisfaction, measured at four
months only).
Cost-effectiveness analyses
In our economic evaluation we adopted the perspective of the
UK NHS and Personal Social Services (Third Party Payer
perspective), with a broader participant and carer perspective
considered in sensitivity analyses. Our primary economic endpoint
was the cost per quality-adjusted life-year at 12-month follow-up.
To assess cost-effectiveness we estimated the additional cost for
delivery of the collaborative care intervention, the costs associated
with health and social care service use, and estimated quality-
adjusted life-years (QALYs). QALYs are a commonly used
summary measure of health-related quality-of-life, taking account
of both quality and quantity of life, and are increasingly used to
compare the cost-effectiveness of interventions across a broad
range of health and related contexts [23]. We estimated QALYs
over the 12-month trial follow-up, using the EQ-5D trial data,
applying UK tariffs obtained from a UK general population
survey to value the EQ-5D health states [24]. In addition, to
inform sensitivity analyses, we used trial data from the SF-36 to
estimate QALYs using the SF-6D, which presents tariffs obtained
from a UK general population survey to value health states [25].
We derived QALY estimates using data from baseline, 4-month
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and 12-month assessments, applying the area-under-the-curve
approach, a recognised approach for assessing repeated measures
data [26], as recommended by Brazier and colleagues [23].
We collected resource use associated with delivery of the
collaborative care intervention within the trial, comprising care
manager contact time, and supervision of care managers by
specialists. We collected other health and social care resource use
by participants over the 12-month follow-up and data on informal
care from friends/relatives and patient costs using self-report,
interviewer administered, questionnaires (at 4 and 12-months;
covering the prior 4-month and prior 8-month time periods
respectively). We collected this same data at the baseline
assessment, with participants reporting resource use over the 6-
month period prior to baseline assessment.
We combined data on resource use with published unit costs to
estimate mean cost per participant by using healthcare resource
values from unit costs in nationally available data sources, adjusted
for inflation where necessary, in British pounds sterling (£) at 2011
costs, see Table 1. In estimates of the intervention cost for
collaborative care, we based care manager costs on costs for UK
NHS Agenda for Change (AfC) band 5 staff costs, using a unit cost
of £65 per hour for patient contact time [27], equivalent to
Mental Health Nurse. This unit cost includes all staff cost
components, and an allowance of contact time to non-contact time
of 1:0.89 (see [27], Table 10.2). We based supervision costs on a
unit cost of £135 per hour for Clinical Supervisors, based on full
costs for specialist mental health professionals at NHS AfC band
8a ([27], Table 9.5).
Statistical methods
We analysed data on an intention-to-treat basis, in accordance
with an analysis plan drawn up prior to the analysis of data [12].
We undertook analyses in STATA, version 12. Our primary
economic analyses estimated mean cost and mean QALY by
treatment allocation, and estimated differences between groups
over 12-months, adjusting for baseline measures, and using pre-
specified covariates for age (individual level), and at the cluster
level covariates for deprivation (IMD), site, and practice size. We
used a multi-level regression model (STATA, xtmixed) for the
primary analyses, to consider the hierarchical (clustered) nature of
the data, presenting the intraclass correlation coefficient (ICC) for
the main analyses. We undertook data analyses using generalised
linear models (GLM), with appropriate family and link compo-
nents, to account for the potentially non-normally distributed
nature of cost data. GLM model results were not different to those
using the multi-level model applied in the main analyses.
Table 1. Unit costs for different types of health and social care resource items.
Resource item
Unit
costs*
Source of
cost data Basis of estimate
GP (at surgery/practice) £36.00 PSSRU 2011 GP appt/surgery; based on costing at 11.7 mins
GP (at home) £121.00 PSSRU 2011
Practice Nurse (surgery) £15.00 PSSRU 2011 15.5 min/hourly patient-related cost
Practice Nurse (home) £30.00 PSSRU 2011 25 min/hourly home visiting cost
Walk-in-centre (appt) £41.00 PSSRU 2011 Walk-in-service (not admitted)
Counsellor £60.00 PSSRU 2011 Per consultation
Mental health worker £76.00 PSSRU 2011 MH Nurse, £76 per 1 hour contact (assumed 1 hr)
Social Worker/Care Manager £212.00 PSSRU 2011 Per 1 hour contact (assumed 1 hr)
Home help/Care Worker £18.00 PSSRU 2011 Per weekday hour
Occupational Therapist £82.00 PSSRU 2011 Community based OT, per 1 hour of client contact (assumed 1 hr)
Voluntary Group (e.g. MIND/CRUISE) £21.73 PSSRU 2010 Cost per user session, voluntary/non-profit organisation (£21 session/2010).
Acute psychiatric ward (bed day) £312.00 PSSRU 2011 Cost per bed day
Long-stay ward (bed day) £222.52 PSSRU 2010 Cost per bed day (£215/2010)
Gen Med ward (bed day) £321.00 PSSRU 2011 weighted ave. All adult mental health inpatient days
A & E (contact) £106.00 PSSRU 2011 Contact, not admitted
Day hospital (Attend/day) £126.00 PSSRU 2011 Cost per day, weighted ave of all adult attendances
Psychiatrist (outpatient contact) £161.38 NHS Ref Costs** 2008–09 per consult (code MHOPFUA2, £155)
Psychologist (outpatient contact) £135.00 PSSRU 2011 Cost per contact hour (assumed 1 hr)
Psychiatric Nurse/Care Coordinator (outpatient contact) £76.00 PSSRU 2011 MH Nurse, £76 per 1 hour contact (assumed 1 hr)
Other Outpatient contact £143.00 PSSRU 2011 Outpatient consultant services, weighted average
Day care centre (comm. serv/social care) £34.00 PSSRU 2011 Cost per user session
Drop in Club (comm. serv/social care) £34.00 PSSRU 2011 Assume cost as day centre, cost per user session
Help from friends/relatives (hrs) £18.00 PSSRU 2011 Use cost per hour, based on unit cost for home help/care worker (as above).
Lost work (day) (friends/relatives) £99.6 ONS 2011 Based on median gross weekly earnings in 2011 for f/t employees at £498.
Travel cost per mile (patient own car) £0.44 Assumed reclaim/expense rate (running cost per mile)
*Unit costs at 2011 prices/costs.
**Costs uprated/adjusted to 2011 prices using HCHS index reported in PSSRU Unit Costs of Health Care [27].
PSSRU Unit Costs of Health Care 2011 [27].
NHS Ref Costs 2008–09 - http://www.ons.gov.uk/ons/dcp171778_256900.pdf (Accessed 18/05/12).
doi:10.1371/journal.pone.0104225.t001
Cost-Effectiveness of Collaborative Care for Depression
PLOS ONE | www.plosone.org 3 August 2014 | Volume 9 | Issue 8 | e104225
Table 2. Mean health and social care resource use (quantities) over 12 month follow-up.
Resource item Usual Care Collaborative Care
n=305 n=276
n
Mean (SD)
[range] n
Mean (SD)
[range]
Primary/Community Care:
GP (surgery/practice) 244 8.21 (6.69)
[0–56]
217 7.77 (6.78)
[0–45]
GP (at home) 247 0.12 (0.80)
[0–11]
218 0.05 (0.27)
[0–3]
Nurse (surgery/practice) 247 1.77 (3.08)
[0–24]
215 1.68 (3.10)
[0–32]
Nurse (at home) 247 0.06 (0.46)
[0–4]
218 0.05 (0.45)
[0–6]
Walk-in-centre (attendance) 247 0.32 (0.87)
[0–8]
217 0.31 (0.86)
[0–5]
Counsellor 246 3.58 (11.26)
[0–116]
212 2.67 (7.21)
[0–48]
Mental Health worker 247 0.58 (3.51)
[0–50]
215 0.79 (3.72)
[0–36]
Social worker 247 0.34 (1.79)
[0–14]
218 0.58 (3.94)
[0–33]
Home help/Care Worker 247 4.35 (47.27)
[0–722]
218 1.24 (15.07)
[0–220]
Occupational Therapist 247 0.22 (0.98)
[0–9]
218 0.13 (0.61)
[0–5]
Voluntary Group 247 0.94 (5.80)
[0–64]
218 0.22 (1.39)
[0–16]
Secondary Care:
Hospital admissions, n+ 247 34 218 28
Acute Psychiatric ward (days) 247 - 218 0.46 (6.77)
[0–100]1
Psychiatric rehab ward 247 - 218 -
Long stay ward 247 0.06 (0.94)
[0–15]
218 -
Psychiatric ICU ward 247 - 218 -
General Medical ward (days) 247 0.48 (2.02)
[0–21]
217 0.42 (1.67)
[0–12]
Other hospital ward/stay 247 0.28 (1.58)
[0–17]
218 0.39 (2.12)
[0–24]
A & E (attendance) 247 0.40 (0.93)
[0–7]
218 0.34 (0.76)
[0–5]
Day hospital (attendance) 247 0.60 (2.22)
[0–24]
218 0.36 (1.19)
[0–12]
Outpatient appointment 247 2.62 (5.60)
[0–58]
217 2.63 (5.63)
[0–65]
Social care:
Used day care services (%)+ 247 3%/2% 218 4%/3%
Day care centre 247 0.28 (4.54)
[0–70]
218 0.07 (1.08)
[0–16]
Drop in club 247 0.56 (5.26)
[0–70]
218 0.12 (1.40)
[0–20]
Day care other 247 0.39 (2.85)
[0–28]
217 0.65 (5.67)
[0–74]
Informal care from friends/relatives:
Had help/care from friends/relatives (%)+ 45%/48% 38%/35%
Hours per week help from friends/relatives# 230 6.11 (15.44)
[0–112]
209 3.95 (10.11)
[0–104]
Report time off work for friends/relatives (%)+ 7%/9% 7%/10%
Cost-Effectiveness of Collaborative Care for Depression
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e104225
We conducted a number of sensitivity analyses for areas of
uncertainty in the cost effectiveness analyses: 1) we considered the
effect of missing data, estimated by multiple imputation (STATA
MI command, with 25 replicated datasets), using all available data
on the target variable together with covariates for individual and
cluster variables used in the base case regression analyses [28]; 2)
we undertook analyses using a broader analytical perspective,
including estimated costs for informal care and participant out-of-
pocket expenses; 3) we analysed data for a scenario using the SF-
6D [25] as an alternative QALY outcome measure; 4) we
considered uncertainty in the intervention costs; 5) we analysed a
scenario where one participant, with an extremely high level of
self-reported resource use, was excluded, as this potentially offers a
more likely and policy-relevant estimate of cost-effectiveness.
We combined estimates of incremental cost and incremental
benefit to present incremental cost effectiveness ratios (ICERs),
allowing decision-makers to assess value for money using the cost
per QALY estimates (ICER= (CostCC–CostTAU)/(QALYCC–QA-
LYTAU)). We used the NICE threshold of £20,000 to £30,000 per
QALY [29,30], i.e. the expected Payer willingness to pay per unit
of additional outcome, to assess the cost-effectiveness of collabo-
rative care, with ICERs below these values regarded as cost-
effective. We used the non-parametric bootstrap approach [31],
with 10,000 replications, to estimate 95% confidence intervals
around estimated cost differences, and for QALY differences, in
order to address uncertainty. To present the level of uncertainty
on cost-effectiveness estimates we used the cost-effectiveness plane
to present combinations of incremental cost and incremental
QALY data from bootstrap replicates, and used the cost-
effectiveness acceptability curve (CEAC), with the ‘net benefit
statistic’ (net monetary benefit = (incremental QALY6willingness
to pay per QALY) –incremental cost)) [32,33], to present the
probability that the intervention is cost-effective (i.e. incremental
net benefit statistic is .0), against a range of potential cost-
effectiveness thresholds.
Results
We recruited a total of 581 participants to the CADET trial,
from 49 practice clusters. The majority (55?6%) of participants
fulfilled criteria for a moderately severe depressive episode with a
further 29?9% meeting criteria for severe depression, 14.3% mild
depression, and 72?6% having suffered from depression in the
past. At baseline, 82% of participants had been prescribed
antidepressant medication by their GP. The mean age was 44?8
years (SD 13?3), and 71?9% were women. A total of 276
participants were allocated to collaborative care and 305 allocated
to usual care. Full trial results have been presented elsewhere [9].
In brief, however, we found that collaborative care improved
depression immediately after treatment compared to usual care,
with effects persisting to 12-month follow-up. After adjustment for
baseline depression, the mean depression score was 1.33 PHQ-9
points lower (95% CI 0.35 to 2.31, p = 0.009) in collaborative care
than in usual care at 4-months, and 1.36 lower (95% CI 0.07 to
2.64, p = 0.04) at 12 months. This difference equated to a
standardised effect size of 0.26 (0.07 to 0.46). Patients receiving
collaborative care had better outcomes than usual care in terms of
depression recovery (odds ratio 1.67 (95% confidence interval 1.22
to 2.29); number needed to treat = 8.4) and response to treatment
(odds ratio 1.77 (95% confidence interval 1.22 to 2.58); number
needed to treat = 7.8).
Cost for Collaborative Care
Our estimated mean cost per participant for the delivery of the
collaborative care intervention was £272.50. This cost estimate
comprises care manager costs at £232, and clinical supervision
costs of £40.50. We based care manager costs on data available
from electronic participant level records on 235 participants
receiving collaborative care, from 10 Care managers, reporting
mean (SD) care manager time per participant of 214.15 (115)
minutes. We based clinical supervision costs on data collected from
supervision records (n = 220 records) reporting a mean supervision
time for care managers, in weekly sessions, at 35 minutes, with six
participants discussed on average per session (based on data from
Table 2. Cont.
Resource item Usual Care Collaborative Care
n=305 n=276
n
Mean (SD)
[range] n
Mean (SD)
[range]
Days lost work by friends/relatives 246 4.05 (29.14)
[0–360]**
217 1.65 (11.28)
[0–144**]
Patient other costs:
OTC medications (£) 246 28.40 (57.90)
[0–429]**
215 40.31 (68.61)
[0–507]**
Travel costs (£) 246 10.98 (30.30)
[0–320]
216 14.33 (37.57)
[0–202]
Own care travel (miles) 246 26.12 (77.68)
[0–600]
214 31.53 (138.95)
[0–1862]
Other ‘one-off’ costs (£) 246 35.77 (144.35)
[0–1569]
218 51.58 (213.53)
[0–1,998]
1includes one participant with 100 days in psychiatric ward/admission.
+Here this data refers to proportion with hospital stay [resource use] at 4 mths follow-up and at 12 months follow-up (mths 5–12) questionnaire.
#this is a weekly number of hours (weighted average of data reported at 4-mth and 12 mth follow-up), and requires652 weeks for annual estimate of hours.
**Kruskal-Wallis (non-parametric) test: no statistically significant differences between groups, other than for OTC cost, and cost for days lost work by friends/
relatives, which are statistically significant at p#0.05.
doi:10.1371/journal.pone.0104225.t002
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164 records). We assumed from this data that participants were
discussed in three supervisory sessions (over the course of the
intervention), at six minutes per participant per session.
Probabilistic analyses used to explore uncertainty around the
main cost component, drawing from the distribution of contact
time for care managers (mean 214.5 mins, SD 115 mins), showed
that in 95% of simulations (cost estimates) the estimated cost of
collaborative care was between £101 and £592 per participant
(median £249).
NHS and Social Care Resource Use and Costs
We found no statistically significant differences between
treatment groups in use of resources during the six months prior
to baseline assessment (see Table S1). Table 2 presents resource
Table 3. Estimated mean cost (£’s) for health, social care, and other resource use, over 12 month follow-up.
Resource item 12-mth Follow-up
Usual Care Collaborative Care
n £ Mean (SD) n £ Mean (SD)
Primary/Community:
GP (surgery/practice) 244 295.52 (241) 217 279.76 (243)
GP (at home) 247 14.21 (97) 218 5.55 (32)
Nurse (surgery/practice) 247 26.54 (46) 215 25.19 (46)
Nurse (at home) 247 1.94 (14) 218 1.38 (13)
Walk-in-centre (attendance) 247 13.28 (35) 217 12.66 (35)
Counsellor 246 214.63 (676) 212 160.47 (433)
Mental Health worker 247 44 (267) 215 59.74 (283)
Social worker 247 72.10 (379) 218 122.53 (835)
Home help/Care Worker 247 78.27 (851) 218 22.38 (271)
Occupational Therapist 247 18.26 (80) 218 10.53 (50)
Voluntary Group 247 20.50 (126) 218 4.88 (30)
Secondary Care:
Acute Psychiatric ward 247 0 218 143.12 (2,113)
Psychiatric rehab ward 247 0 218 0
Long stay ward 247 13.51 (212) 218 0
Psychiatric ICU ward 247 0 218 0
General Med ward 247 154.65 (649) 217 134.61 (535)
Other hosp ward/stay 247 90.97 (507) 218 123.69 (682)
A & E 247 43.06 (99) 218 36.47 (81)
Day hospital 247 74.99 (280) 218 45.08 (150)
Out Patient Appt, Psychiatrist 247 26.79 (148) 217 43.88 (170)
Out Patient Appt, Psychologist 247 25.14 (313) 217 25.51 (296)
Out Patient Appt, Psychiatric Nurse 247 8.92 (67) 217 12.61 (166)
Out Patient Appt, Other 246 306.93 (588) 215 285.34 (498)
Social care:
Day care centre 247 9.64 (151) 218 2.50 (37)
Drop in club 247 19.13 (179) 218 4.06 (48)
Day care other 247 13.35 (97) 217 22.09 (193)
Informal care from friends/relatives:
help from friends/relatives 230 5,714.73 (14,455) 209 3,698.50 (9,462)
Days lost work by friends/relatives 246 403.26 (2,902) 217 164.78 (1,123)
Patient other costs:
OTC medications 246 28.40 (58) 215 40.31 (69)
Travel costs 246 10.98 (30) 216 14.33 (38)
Own car travel 246 11.75 (35) 214 14.19 (63)
‘one-off’ costs 246 35.77 (144) 218 51.58 (213)
Kruskal-Wallis (non-parametric) test: no statistically significant differences between groups, other than for OTC cost, and cost for days lost work by friends/
relatives, which are statistically significant at p#0.05.
(Appt= appointment; OTC=over the counter).
doi:10.1371/journal.pone.0104225.t003
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use over the 12-month follow-up, and Table 3 presents the costs
associated with resource use over 12-month follow-up. Table 4
presents cost data by category with comparison by category by
treatment group. We found a broadly similar pattern of resource
use across groups, with estimated mean costs for NHS and social
care (Third Party Payer perspective), excluding the collaborative
care intervention, at £1,571 and £1,614 respectively for usual
care and collaborative care participants. After adjustment for
baseline cost and individual and cluster covariates the cost
difference was not statistically significant, with wide confidence
intervals. When including the cost for the collaborative care
intervention, the mean total NHS and social care costs were
£1,571 and £1,887 for usual care and collaborative care
participants respectively, but similarly, after adjustment the cost
difference of £271 was not statistically significant. Excluding the
intervention cost, the one area of substantial cost difference
between groups was on hospital stay, with a mean cost difference
of £161 (regression adjusted estimate). This estimated difference in
hospital cost was driven by one participant in the collaborative
care group, who reported an acute psychiatric hospital stay of 100
days. When we excluded that one participant from analyses, the
cost difference for hospital stay was adjusted to £34 (–119 to 189),
and the related differences in NHS and social care, without
collaborative care costs and with collaborative care costs, were
adjusted to –£209 (less cost for collaborative care), and £63
(additional cost for collaborative care) respectively.
Broader Participant Level and Social Costs
Tables 2 and 3 report resource use and cost estimates associated
with informal care from friends and/or relatives, and other patient
out-of-pocket expenses. Our findings show that informal care
costs, when estimated using a shadow price for informal care (an
estimate of £18 per hour, see Table 1), represented the largest
resource and cost burden associated with participants’ depression.
Participants in the treatment as usual group reported a high use of
informal care, which resulted in a higher mean (SD) cost estimate,
over 12-months, at £5,715 (£14,455) compared to £3,699
(£9,462) in the collaborative care group. However there is wide
variation in the self-report data as shown by the large standard
deviations. When adjusting for baseline costs and other covariates
the difference in estimated cost for informal care was –£1,114
(95% CI –£3,366 to £1,117), with lower costs for the collaborative
care group, and, therefore, lower total costs in the collaborative
care group (Table 4).
Quality-Adjusted Life-Years
Table 5 reports data on health state values for the EQ-5D and
the SF-6D, and the estimated QALY values over 12-months.
When adjusted for baseline and for individual and cluster
covariates we found a difference of 0.02 (95% CI –0.02 to 0.06)
in the QALY over 12 months for the EQ-5D, and 0.017 (95% CI
0.000 to 0.032) for the SF-6D. Both measures showed a QALY
Table 4. Estimated costs, and cost differences (adjusted, unadjusted), over 12-month follow-up, by group.
Resource item
Usual Care
n=305
Collaborative
Care n=276
Difference
(no adjustment)
Difference, adjusted for baseline
and
participant/cluster covariates*
n Mean (SD) £ n Mean (SD) £ £ Mean (95% CI)** £
Primary and community
services/care
243 801.49 (1,476.98) 208 715.86 (1,220.06) –85.63 –116.48 (–341.06, 110.91)
Secondary care: hospital
stay
247 259.14 (835.40) 217 402.65 (2,282.88) 143.51 160.92 (–70.81, 481.70)
Secondary care:
outpatient care
246 368.03 (781.43) 215 368.09 (692.60) 0.06 –30.68 (–148.85, 111.70)
Secondary care: day
hospital
247 74.99 (280.31) 218 45.08 (149.65) –29.91 –14.52 (–50–13, 17.94)
A & E 247 42.06 (98.66) 218 36.47 (80.51) –5.59 –5.87 (–22.39, 9.99)
Day services and care 247 42.12 (334.85) 217 28.67 (203.43) –13.45 1.83 (–38.51, 41.01)
Total NHS and personal
social services (excl
Collab Care)
242 1,570.70 (2,441.55) 205 1,614.32 (3,714.49) 43.62 1.78 (–454.82, 640.81)
CADET collaborative
care
- 272.50 272.50 -
Total NHS and personal
social services
242 1,570.70 (2,441.55) 205 1,886.82 (3,714.49) 316.12 270.72 (–202.98, 886.04)#1
Patient personal costs
(OTC/meds, travel costs,
plus patient ‘one-off’ costs)
244 86.64 (175.50) 211 120.79 (260.37) 34.15 24.95 (–12.41, 65.61)
Informal care costs 230 5,714.73 (14,455.18) 209 3,698.50 (9,642.61) –2,016.23 –1,114.13 (–3,366.09, 1,117.32)
TOTAL costs (NHS
and patient/related costs)
223 7,010.59 (13,492.42) 195 5,764.48 (10,796.40) –1,246.11 –312.83 (–2,339.92, 2,035.27)#2
*regression analyses using multilevel model (‘xtmixed’ STATA), with baseline value as covariate, age, and cluster level covariates.
**95% Confidence intervals estimated using non-parametric bootstrap method.
#1ICC= 0.0000 (95% CI 0.0000, 0.0000).
#2ICC= 0.0000 (95% CI 0.0000, 0.0000).
On cost estimates for individual items/categories, ANOVA showed no statistically significant differences between groups; [note: informal care cost difference at p = 0.088].
doi:10.1371/journal.pone.0104225.t004
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gain for collaborative care, although the EQ-5D difference is not
statistically significant.
Cost-Effectiveness Analyses
Table 6 presents data used to estimate cost per QALY, and the
cost per QALY estimates, based on participants with data on costs
and outcomes at follow-up. The base case cost per QALY for
collaborative care was £14,248, adopting a NHS and social care
perspective, with uncertainty around this estimated illustrated in
Figure 1 (cost-effectiveness plane), and Figure 2 (CEAC). The
probability that collaborative care is cost effective, compared to
treatment as usual, is 0.58 at a willingness to pay of £20,000 per
QALY, and 0.65 at a willingness to pay of £30,000 per QALY.
Sensitivity Analyses
Table 6 presents the results of our sensitivity analyses, where we
estimated incremental costs and QALYs, and cost per QALY
using alternative assumptions. In base case analyses 23% of cost
data are missing at 12-month follow-up (21% in control; 25% in
collaborative care), and 20% of QALY (EQ-5D) data are missing
at the 12-month follow-up (19% in control; 21% missing in
collaborative care). Imputation of missing data resulted in an
estimated incremental cost of £292 and an incremental EQ-5D
QALY gain of 0.017, with a cost per QALY of £17,490. Where
we adopted a broader analytical perspective, including all
participants with data on cost and outcome at follow-up, we
estimated a mean cost saving of £313 with collaborative care,
alongside the estimated incremental gain in QALYs (0.02). This,
therefore, represents a position of dominance for the collaborative
care intervention compared to treatment as usual. Using the SF-
6D QALY estimate the cost per QALY increased to £16,114, with
a 0.57 and 0.72 probability of being cost-effective at a willingness
to pay of £20,000 and £30,000 per QALY respectively. When we
analysed CEA using an alternative cost for the collaborative care
intervention, assuming a cost of £338.80 per participant
(compared to base case of £272.50) to allow for additional clinical
supervision time to the care manager, and therefore per
participant, and for supervision from a psychiatrist (unit cost per
hour, £267, [27]) the base case cost per QALY estimate increased
to £17,738. When we undertook a scenario the same as the base
case but with one participant, with extremely high resource use,
excluded from analyses the cost per QALY was reduced to an
estimate of £3,334 with a 0.76 and 0.79 probability of being cost-
effective at a willingness to pay of £20,000 and £30,000 per
QALY respectively.
Discussion
Our results show that collaborative care is cost-effective,
compared to usual care, in treating people with depression in a
UK primary care setting, where providers are willing to pay up to
£20,000 per QALY gained. When taking a broader analytical
perspective, and including costs associated with informal care,
results show that collaborative care is expected to be cost saving,
with expected health gains, and therefore dominates the usual care
comparator. Previous reviews [10,34] have reported on economic
analyses related to collaborative care, across a range of settings,
including care for depression. These reviews have identified
evidence from cost-utility (cost per QALY) studies to support the
economic value of collaborative care for depression in the United
States healthcare system, and have also highlighted an absence of
evidence for the UK. Results presented here for the CADET trial
represent the first study to estimate the cost-effectiveness of
collaborative care in a UK primary care setting.
Our cost-effectiveness analyses report an expected modest mean
QALY gain at a relatively low cost. The relative effectiveness of
collaborative care versus usual care reported in the CADET trial
[9] is regarded as clinically meaningful in terms of recovery
(defined as a follow up score of less than or equal to 9 on PHQ-9)
Table 5. Health State Values and QALY comparisons (adjusted, unadjusted), over 12-month follow-up, by group.
Measure (time-point) Usual Care n=305 Collaborative Care n=276
Difference
(no adjustment)
Difference, adjusted for
baseline and participant/cluster
covariates*
n
Mean (SD)
[range] n
Mean (SD)
[range] Mean (95% CI)**
EQ-5D: Baseline 305 0.464 (0.313)
[–0.29, 1.00]
276 0.504 (0.288)
[–0.349, 1.00]
0.040
EQ-5D: 4-month 273 0.557 (0.331)
[–0.239, 1.00]
228 0.599 (0.341)
[–0.484, 1.00]
0.042
EQ-5D: 12-month 254 0.593 (0.338)
[–0.349, 1.00])
227 0.650 (0.317)
[–0.484, 1.00])
0.057
EQ-5D: QALY
(12-month)
248 0.554 (0.286)
[–0.27, 0.97]
218 0.605 (0.261)
[–0.29, 0.97]
0.051* 0.019 (–0.019, 0.06)#
SF-6D: Baseline 303 0.538 (0.86)
[0.30, 0.77]
274 0.540 (0.83)
[0.30, 0.82]
0.002
SF-6D: 4-month 269 0.597 (0.126)
[0.30, 1.00]
227 0.614 (0.140)
[0.32, 1.00]
0.017
SF-6D: 12-month 250 0.605 (0.131)
[0.30, 1.00])
223 0.634 (0.144)
[0.30, 1.00])
0.029*
SF-6D: QALY
(12-month)
241 0.591 (0.109)
[0.30, 0.90]
211 0.609 (0.114)
[0.35, 0.91]
0.018 0.0168 (0.000, 0.032)
#ICC = 0.0000 (95% CI 0.0000, 0.0000).
*ANOVA, p#0.05.
**regression analyses using multilevel model (‘xtmixed’ STATA), with baseline.
doi:10.1371/journal.pone.0104225.t005
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and treatment response (defined as a 50% reduction or greater at
follow up compared to baseline PHQ-9). Although, as seen in the
QALY data, the average individual treatment response was
modest, at 12 months 56% of patients receiving collaborative care
were ‘recovered’, 15% more than in usual care, and 49%
responded to treatment, 13% more than in usual care. Whilst
the mean QALY gains are modest, they are comparable, and
favourable, to those recently reported for evaluation of a UK
Improving Access to Psychological Therapies (IAPT) service [35],
which estimated a mean EQ-5D QALY gain of 0.014 (SF6D gain
of 0.008). In the IAPT evaluation, the SF6D values at baseline and
follow-up are a little higher than those for CADET, probably
reflecting the fact that the patient group had a lower mean PHQ-9
score compared to CADET participants. Our estimated costs for
health and social care in CADET are similar to those reported in
the IAPT service evaluation, for IAPT service or comparator
mental healthcare services [35]. QALY gains from the collabora-
tive care intervention are in a similar range to those reported for
evaluation of therapist-delivered CBT for depression [36], where a
mean (95% CI) incremental QALY benefit is reported at 0.027 (–
0.012 to 0.066).
Our base case difference in health and social care (NHS and
PSS) costs, over 12 months (£271), and the subsequent cost per
QALY estimate, of £14,248 are heavily influenced by one
participant who reported extremely high levels of service use for
specialist care, including a 100-day stay in an acute psychiatric
hospital. This participant, in the collaborative care group, had an
estimated service use cost of £48,522, compared to a mean cost of
£1,637 for all other trial participants with cost data over 12-
months (n = 446); 94% of participants have cost estimates at less
than £5,000; all but four participants have costs at less than
£10,000; three participants have costs estimated between £10,000
and £24,000. When we excluded this one participant from
analyses, the difference in NHS and PSS costs, when including
cost for collaborative care, was £63, between collaborative care
and usual care, with an estimated cost per QALY of £3,334. For
Table 6. Cost Effectiveness Analyses.
Scenario/Analyses
Difference, adjusted for
baseline and
participant/cluster
covariates* Mean
(95% CI)
ICER, Cost (£)
per QALY
Probability Cost-
effective at WTP`
per QALY gained:
£20,000 per QALY £30,000 per QALY
Base Case:
Total NHS and personal social services £270.72
(–202.98, 886.04)
EQ-5D: QALY (12-month) 0.019
(–0.019, 0.06)
£14,248 0.58 0.65
Sensitivity Analyses:
(1) Base Case CEA, with
multiple imputation of
missing data
Total NHS and personal social services £292.08
(–216.88, 801.04)
EQ-5D: QALY (12-month) 0.017
(–0.020, 0.054)
£17.490 N/A N/A
(2) CEA Using SF6D QALY data
SF6D: QALY (12-month) 0.0168
(0.000, 0.032)
£16,114 0.57 0.72
(3) CEA when excluding
one high cost participant
Total NHS and personal social services £63.34
(–295.98, 422.67)
EQ-5D: QALY (12-month) 0.019
(–0.018, 0.06)
£3,334 0.76 0.79
(4) CEA using higher cost
estimate for Collaborative
Care, at mean
cost of £338.80
Total NHS and personal social services £337.02
(–136.67, 952.34)
£17,738 0.54 0.62
(5) CEA using a broader
perspective, including patient
costs and informal
care costs
–£312.83
(–2,339.93, 2,035.27)
Collaborative Care is dominant** N/A N/A
*Adjusting for baseline measures, and pre-specified covariates for age (individual level), and (at the cluster level) deprivation (IMD), site, and practice size.
**Dominance: lower expected costs, with greater expected QALY gain.
`WTP=willingness to pay; based in the assessment of incremental net benefit statistic, and WTP thresholds commonly applied in the UK NHS (NICE, 2013).
doi:10.1371/journal.pone.0104225.t006
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our primary analysis we retained the intent to treat principle, and
this one participant is included in the base case analyses, but we
would suggest that the likely cost-effectiveness of collaborative care
in practice might be closer to the estimate in the sensitivity
analyses with this one participant excluded.
Although there is uncertainty in the cost and QALY data, our
probabilistic analyses indicate that collaborative care has a 58% or
65% probability of being cost-effective, at commonly assumed UK
NHS willingness to pay of £20,000 or £30,000 per QALY. Where
we considered uncertainty around the CEA estimate that excludes
one participant with high service use and costs (£3,334 per
QALY), the probability of being cost effective at these cost per
QALY thresholds is above 75%. Given the wide variation in the
costs reported for general health and social care resource use, and
the uncertainty in the profile of resource use, a simplistic view
would be to have an expectation that the introduction of
collaborative care will involve an additional cost of £272.50 per
participant for the UK NHS, and this potential cost alongside
estimated EQ-5D QALY gains, results in an expected cost per
QALY gain of £14,342, which is similar to the base case analyses
presented here and represents a cost effective use of NHS
resources.
Strengths and Limitations
The CADET trial was a high quality RCT with an integrated
economic evaluation, reported here. The analyses follow good
practice for economic evaluation, and our within-trial analysis
demonstrates cost-effectiveness at the willingness to pay threshold
of £20,000 per QALY, without the need to extrapolate potential
benefits over the longer term. Our analyses use data collected
within trial to estimate resource use and cost associated with
delivery of the intervention, but rely on self-report data, from
interviewer administered questionnaires, to estimate health and
social care service use, and to estimate broader resource impacts.
There is no consensus in the economic evaluation literature on the
relative merits of different methods for collection of resource use
data [37–39], but routinely collected service use data may have
provided a more rigorous estimate of service use, particularly for
primary care contacts [40]. However, there are difficulties and
costs related to collection of service use data from 42 general
practices, and from other necessary routine data collection for
aspects of care not recorded in GP records, therefore we chose to
use participant self-report data. Difficulties collecting detailed data
via self-report on medications, related to potential for variation in
medication names, dose, the potential for people to be on
medications for a wide range of co-morbid conditions, and other
factors, can lead to errors in self-reporting. These issues led to the
exclusion of medication costs from the economic analysis plan
[12], and this may be a limitation in the results presented here, as
medication adherence has been shown to be one of the potential
benefits from collaborative care [8]. However, most participants in
both collaborative care and the usual care groups remained on
antidepressant prescriptions (74.8% v 73.8% at four months;
69.7% v 69.2% at 12 months).
The perspective on the analyses do not extend to the broad
welfare and economic impacts of depression, including impact on
productivity costs, as such costs are not included in the reference
case analyses suggested by NICE [29] for UK analyses. However,
data collection did cover aspects of care and support, and patient
costs that have extended the primary perspective (of NHS and PSS
costs) to a broader patient and societal orientated perspective. We
Figure 1. Cost-effectiveness plane (Payer perspective).
doi:10.1371/journal.pone.0104225.g001
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accept that the use of a relatively small number of categories for
these broader considerations may be a limitation in the analyses.
However, as in other studies (e.g. [41]) we found that resources,
and estimated costs, associated with informal care were a
dominant aspect of care and costs, when taking a wider
perspective, and provided clear guidance on the magnitude of
costs at a wider perspective.
As discussed above, our estimated differences in costs, and in
EQ-5D QALYs, did not reach statistical significance, introducing
some uncertainty. However, the methods used in cost-effectiveness
analyses account for uncertainty through replication of the
estimates of incremental costs and QALYs, using the non-
parametric bootstrap approach. The presentation of uncertainty
using the CEAC, allows decision makers to consider the likelihood
of collaborative care providing a cost-effective use of resources.
Implications
The CADET trial has shown that collaborative care improves
depression immediately after treatment compared to usual care, it
also has effects that persist to 12 month follow-up and is preferred
by patients over usual care, and here our economic analysis of
collaborative care also shows that it is cost effective in the UK. We
have therefore, responded to the evidence needs, and answered the
specific request for evidence required by NICE [11], on the
clinical and cost effectiveness of collaborative care, in that our
positive findings on the cost-effectiveness of collaborative care adds
to the evidence for its sustained clinical effectiveness.
Given that collaborative care is more effective over a sustained
period of time than usual care and represents value for money
against commonly used thresholds for cost per QALY, we suggest
that commissioners of healthcare in the UK and elsewhere
organise their depression management services using a collabora-
tive care model. Evidence here indicates that services should be
commissioned to support the management of patients with
depression in UK primary care using a collaborative care model,
as it would be both effective and cost effective to do so. Although
the introduction of collaborative care will involve additional
resources for the delivery of the intervention, there is reasonable
potential for cost saving against other areas of health and social
care over time.
Where we have included informal care costs in our analyses, the
finding that collaborative care is the dominant intervention,
compared to care as usual, is an important issue. Family members
and others involved in informal care are contributing to the care of
depression in a substantial manner. As Richard Layard and others
have often asserted [42], the implications of these care costs on
productivity is a significant burden on the economic activity of a
nation. The introduction of collaborative care has the potential to
relieve some of the significant burden that falls on informal carers,
and can reduce this economic load.
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